Edition:
United States

AzurRx BioPharma Inc (AZRX.OQ)

AZRX.OQ on NASDAQ Stock Exchange Capital Market

2.94USD
14 Dec 2017
Change (% chg)

-- (--)
Prev Close
$2.94
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
12,942
52-wk High
$5.25
52-wk Low
$2.40

Summary

Name Age Since Current Position

Edward Borkowski

58 2015 Independent Chairman of the Board

Maged Shenouda

53 2017 Chief Financial Officer, Executive Vice President - Corporate Development & Independent Director

Daniel Dupret

60 Chief Scientific Officer

Charles Casamento

71 2017 Director

Vern Schramm

2017 Director

Alastair Riddell

67 2015 Independent Director

Biographies

Name Description

Edward Borkowski

Mr. Edward J. Borkowski, CPA, serves as Independent Chairman of the Board of the Company. He joined our board of directors in May 2015 and was appointed Chairman of our board of directors in September 2015. In May 2015, Mr. Borkowski joined the board of Concordia Healthcare. In February 2016, he joined Concordia as its Executive Vice President and continues to serve on its board of directors. Between September 2013 and February 2016, Mr Borkowski was the Chief Financial Officer of Amerigen Pharmaceuticals, an early stage, private, generic pharmaceutical company. From May 2012 to June 2013, Mr. Borkowski served as the Chief Financial Officer of ConvaTec Inc., a private global medical products and technologies company. From January 2011 to May 2012, Mr. Borkowski served as a consultant and advisor to several investment and private equity firms relating to investing in the medical technology and generic pharmaceutical industry. From May 2009 to December 2010, Mr. Borkowski served as the Chief Financial Officer of CareFusion Corporation, a global healthcare company focused on pharmaceutical dispensing equipment, infusion pumps, ventilators and surgical instruments. From 2002 through 2009, Mr. Borkowski was the Chief Financial Officer of Mylan Labs, one of the largest generic and specialty pharmaceutical companies in the world. Mr. Borkowski received his M.B.A. from Rutgers University and his B.S. from Allegheny College. He is also a Certified Public Accountant and a member of the AICPA and NYSSCPA.

Maged Shenouda

Mr. Maged S. Shenouda is Chief Financial Officer, Executive Vice President - Corporate Development & Independent Directorof the Company. He joined our board of directors in October 2015. Mr. Shenouda, a financial professional in the biotechnology industry, was the head of Business Development at Retrofin, Inc. from January 2014 until November 2014. From January 2012 until September 2013, he served as Head of East Coast Operations for the Blueprint Life Science Group. Prior thereto, Mr. Shenouda was a financial analyst, first at UBS from January 2004 until March 2010 and Stifel Nicolaus from June 2010 until November 2011. He currently serves on the board of directors of Protea and was appointed to our board as Protea’s designee pursuant to the terms of the SPA.

Daniel Dupret

Mr. Daniel Dupret serves as Chief Scientific Officer of the Company. He has served as President of AzurRx SAS since its formation in 2007 and as Chief Scientific Officer of our company since the Acquisition. Previously, Dr. Dupret founded Proteus SA in 1998 and served as its President and CEO from 1998 to 2007. He founded Appligene SA in 1985 and served as its CSO, then President and CEO until 1998. From 1982 to 1985, he served as Project leader at Transgene SA. In parallel to his biotechnology career, Daniel Dupret served as an advisor for the French government and the European commission in connection with grant commission and funding of early-stage biotechnology companies. From 2003 to 2007, he served as President of the Board of the University of Nîmes.

Charles Casamento

Mr. Charles J. Casamento is Director of the company. Mr. Casamento is currently Executive Director and Principal of The Sage Group, a healthcare advisory group specializing in mergers, acquisitions, and partnerships between biotechnology companies and pharmaceutical companies, since 2007. He was the president and CEO of Osteologix, Inc., a public biopharmaceutical company developing products for treating osteoporosis, from 2004 through 2007. From 1999 through 2004, he served as chairman of the board, president and CEO of Questcor Pharmaceuticals, Inc. which was subsequently acquired by Mallinckrodt. Mr. Casamento formerly served as RiboGene, Inc.’s president, CEO and chairman of the board from 1993 through 1999 until it merged with Cypros to form Questcor. He was co-founder, president and CEO of Interneuron Pharmaceuticals, Inc. (Indevus), a biopharmaceutical company, from 1989 until 1993. Indevus was eventually acquired by Endo. Mr. Casamento also serves on the Board of Directors of Relmada Therapeutics, Inc. and International Stem Cell Corporation. He is Chairman of the Audit Committee at Relmada. He has served as a guest lecturer at Fordham University and is on the Science Council of Fordham University. He holds a bachelor’s degree in Pharmacy from Fordham University and an M.B.A. from Iona College.

Vern Schramm

Dr. Vern Schramm is Director of the company. He is currently a Professor and Chairman of the Department of Biochemistry at the Albert Einstein College of Medicine, where he has taught for over thirty years. Prior to that, Dr. Schramm was a professor at Temple University School of Medicine. Dr. Schramm currently sits on the Metabalon Biochemistry Advisory Board and Sirtris Scientific Advisory Board, acts as a consultant for BioCryst Pharmaceuticals, and is the Scientific Co-founder of Pico Pharmaceuticals. Dr. Schramm has been elected to the National Academy of Sciences, has sat on several committees and advisory boards, presented at numerous events around the world, and has authored numerous original research publications. Dr. Schramm holds a B.S. in Bacteriology from South Dakota State College, a Master's Degree in Nutrition with a biochemistry emphasis from Harvard University, and a Ph.D. in Mechanism of Enzyme Action from Australian National University.

Alastair Riddell

Mr. Alastair Riddell serves as Independent Director of the Company. He joined our board of directors in September 2015. Since September 2012, Dr. Riddell has served as the Chairman of Definigen Ltd. and has served as the Chairman of both Silence Therapeutics Ltd. since November 2013 and Procure Therapeutics from October 2009 to November 2012. From 2007 to 2009, he served as the Chief Executive Officer of Stem Cell Sciences, Inc. and from 2005 to 2007, he served as the Chief Executive Officer of Paradigm Therapeutics. From 1998 to 2005, Dr. Riddell served as the Chief Executive Officer of Pharmagene Laboratories Ltd.

Basic Compensation

Name Fiscal Year Total

Edward Borkowski

--

Maged Shenouda

--

Daniel Dupret

204,675

Charles Casamento

--

Vern Schramm

--

Alastair Riddell

--
As Of  30 Dec 2015